Rivaroxaban to reduce risk of CV eventsDecember 13, 2018
The US FDA has approved rivaroxaban (Xarelto), 2.5 mg twice daily, plus aspirin low dose once daily to reduce the risk of major cardiovascular events, including cardiovascular (CV) death.
Rivaroxaban is a non-vitamin K antagonist oral anticoagulant (NOAC).
For the approval, the FDA reviewed data from the phase III COMPASS study, which showed that rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily reduced the
risk of the composite of stroke, CV death and heart attack by 24 percent compared with aspirin 100 mg once daily alone in patients with CAD or PAD.
Rivaroxaban was discovered by Bayer, and is being jointly developed with Janssen Research & Development, LLC.